HOME >> BIOLOGY >> NEWS
New advances in thrombosis help further understanding of disease prevention

(San Diego, Calif., December 6, 2003) Several studies presented during the 45th Annual Meeting of the American Society of Hematology shed light on some promising new therapies that are in the pipeline for the treatment of thrombosis, as well as some potential risk factors, and may provide hope for the numerous patients suffering from this condition.

Thrombosis, or more specifically deep vein thrombosis (DVT), is a dangerous medical condition in which the formation of a blood clot blocks circulation in the deep veins of the lower limbs that are primarily responsible for returning deoxygenated blood to the heart. A number of factors contribute to one's risk of developing a clot, including age, obesity, major surgery, trauma or immobility, genetic factors, oral contraceptives, or hormone replacement therapy. Risk is higher when more than one risk factor is present. Blood clots can become potentially fatal if the clot breaks loose from the wall of the vein and migrates from the leg to the lungs, called pulmonary embolus (PE). When this happens, clots block a pulmonary artery or one of its branches, disrupting the lung's blood flow and the addition of oxygen to the blood.

Drugs used to treat deep vein thrombosis fall into three general classes: (1) anticoagulants, which inhibit blood coagulation and serve to weaken already formed clots, preventing further expansion; (2) thrombolytic agents, which actually help to dissolve clots; and (3) antiplatelet agents, which decrease activation of platelets and prevent new clots from being formed.

"Since we are aware of the risk factors, deep vein thrombosis should be a preventable occurrence," said Jim George, M.D. Vice President of the American Society of Hematology and Professor of Medicine at the University of Oklahoma Health Sciences Center, Oklahoma City. "Current therapies, though somewhat effective, still have many limitations and undesirable side effects. Technological advancement
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Society of Hematology
6-Dec-2003


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Grant advances biochemical engineering laboratory
2. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
3. Undergraduate research experience advances education
4. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
5. UCSF finding advances insight into adult stem cells in human brain
6. Federal grant supports advances in infant heart disease at Childrens Hospital of Philadelphia
7. Human embryonic stem cells may promise medical advances
8. Scientists making advances in cancer prevention, detection and treatment to receive awards
9. Conference to highlight medical advances resulting from 50 years of DNA knowledge
10. Annual bibliography of significant advances in dietary supplement research 2002
11. Dartmouth study advances prion disease research

Post Your Comments:
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Smarter ... outdoor security solutions, today announced that Genzyme, a Sanofi ... units of Door Detective® CL for a multi-use facility ... installed in four other Genzyme buildings, this latest order ... with the tailgate detection device improving doorway ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... May 21, 2013 NANONEX CORPORATION, ... solutions , today announced the successful delivery and ... system, the NX-M200B, to a major Japanese manufacturing ... a fully-automated, production-ready, advanced nanoimprint lithography tool that ... wafer and substrate sizes and types. Based on ...
(Date:5/21/2013)... 2013 PathoGenetix, Inc., a commercial-stage developer ... announced today that it has successfully identified and strain ... obtained from the Centers for Disease Control and Prevention ... The findings are detailed in a poster ... for Microbiology in Denver on Monday. , The 250 ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
Cached News: